Cargando…

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease

The plant alkaloid galantamine is an established symptomatic drug treatment for Alzheimer’s disease (AD), providing temporary cognitive and global relief in human patients. In this study, the 5X Familial Alzheimer’s Disease (5XFAD) mouse model was used to investigate the effect of chronic galantamin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharya, Soumee, Haertel, Christin, Maelicke, Alfred, Montag, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931790/ https://www.ncbi.nlm.nih.gov/pubmed/24586789 http://dx.doi.org/10.1371/journal.pone.0089454

Ejemplares similares

Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease
por: Bhattacharya, Soumee, et al.
Publicado: (2015)

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
por: Baakman, Anne C., et al.
Publicado: (2016)

Myeloperoxidase Deficiency Inhibits Cognitive Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Volkman, Rotem, et al.
Publicado: (2019)

Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer’s disease
por: Park, Sohui, et al.
Publicado: (2021)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

The effect of electroconvulsive therapy on neuroinflammation, behavior and amyloid plaques in the 5xFAD mouse model of Alzheimer’s disease
por: Svensson, Martina, et al.
Publicado: (2021)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome
por: Simoes de Souza, Fabio M., et al.
Publicado: (2011)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer’s disease mouse model 5xFAD
por: Boza-Serrano, Antonio, et al.
Publicado: (2018)

Distribution and inter-regional relationship of amyloid-beta plaque deposition in a 5xFAD mouse model of Alzheimer’s disease
por: Tsui, Ka Chun, et al.
Publicado: (2022)

Cyclopentanone Derivative Attenuates Memory Impairment by Inhibiting Amyloid Plaques Formation in the 5xFAD Mice
por: Ullah, Rahim, et al.
Publicado: (2021)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen
por: Thavichachart, N, et al.
Publicado: (2006)

Longitudinal Consumption of Ergothioneine Reduces Oxidative Stress and Amyloid Plaques and Restores Glucose Metabolism in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Whitmore, Clayton A., et al.
Publicado: (2022)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease
por: Sadleir, Katherine R., et al.
Publicado: (2018)

Inhibition of REV‐ERBs stimulates microglial amyloid‐beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer’s disease
por: Lee, Jiyeon, et al.
Publicado: (2019)

Fluorescent indolizine derivative YI-13 detects amyloid-β monomers, dimers, and plaques in the brain of 5XFAD Alzheimer transgenic mouse model
por: Kim, DaWon, et al.
Publicado: (2020)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Lowering hippocampal miR-29a expression slows cognitive decline and reduces beta-amyloid deposition in 5xFAD mice
por: Mei, Zhen, et al.
Publicado: (2023)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Correction: Fluorescent indolizine derivative YI-13 detects amyloid-β monomers, dimers, and plaques in the brain of 5XFAD Alzheimer transgenic mouse model
por: Kim, DaWon, et al.
Publicado: (2021)

Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer’s Disease
por: Yang, Eun-Jeong, et al.
Publicado: (2015)

Synaptosomal Mitochondrial Dysfunction in 5xFAD Mouse Model of Alzheimer's Disease
por: Wang, Lu, et al.
Publicado: (2016)

Axonal and myelinic pathology in 5xFAD Alzheimer’s mouse spinal cord
por: Chu, Tak-Ho, et al.
Publicado: (2017)

Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer’s disease
por: Lim, Jeremiah K. H., et al.
Publicado: (2021)

Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease
por: Forner, Stefania, et al.
Publicado: (2021)

Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer’s Disease Mouse Model
por: Jeong, Ye Ji, et al.
Publicado: (2021)

Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer’s disease
por: Govindarajan, Karthivashan, et al.
Publicado: (2023)

Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
por: Bader, Angelika Sabine, et al.
Publicado: (2023)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model
por: Shin, Jisu, et al.
Publicado: (2021)

Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer’s disease
por: Sethi, Mansi, et al.
Publicado: (2015)

Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer’s disease
por: Kesler, Shelli R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ud8a5fchuef0fl81crg2lf1vm